Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 4/2006

Open Access 01-12-2006 | Research

The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence

Authors: Kari Hemminki, Charlotta Granström, Jan Sundquist, Justo Lorenzo Bermejo

Published in: Hereditary Cancer in Clinical Practice | Issue 4/2006

Login to get access

Abstract

The Swedish Family-Cancer Database has been used for some 10 years in the study of familial risks at all common sites. In the present paper we describe some of the main features of version VII of this Database, assembled in year 2006. This update included all residents in Sweden born or immigrated in 1932 and later (offspring) with their biological parents, a total of 11.5 million individuals. Cancer cases were retrieved from the Swedish Cancer Registry from years 1958 to 2004, including over 1.2 million first and multiple primary cancers and in situ tumours. We show one application of the Database in the study of familial risks in prostate cancer, with special reference to the modification of familial risk at the time of about 50% increase in incidence due to prostate specific antigen (PSA) screening. The familial risks for prostate cancer were 1.92 for sons of affected fathers, 3.03 for brothers and 5.44 for men with an affected father and an affected brother. Familial risk for prostate cancer according to the time since the first family member was diagnosed showed significant increases for two family members being diagnosed in the same year compared to 5+ years apart. Increased surveillance and the availability of PSA screening are the likely reasons for the overestimated familial relative risk shortly after the first diagnosis. This lead time bias should be considered in clinical counselling.
Literature
1.
go back to reference American Society of Clinical Oncology: American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003, 21: 2397–2406. 10.1200/JCO.2003.03.189CrossRef American Society of Clinical Oncology: American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003, 21: 2397–2406. 10.1200/JCO.2003.03.189CrossRef
2.
go back to reference Hampel H, Sweet K, Westman JA, Offit K, Eng C: Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004, 41: 81–91. 10.1136/jmg.2003.010918PubMedCentralCrossRefPubMed Hampel H, Sweet K, Westman JA, Offit K, Eng C: Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004, 41: 81–91. 10.1136/jmg.2003.010918PubMedCentralCrossRefPubMed
3.
go back to reference Epplein M, Koon KP, Ramsey SD, Potter JD: Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol 2005, 23: 4713–4718. 10.1200/JCO.2005.00.133CrossRefPubMed Epplein M, Koon KP, Ramsey SD, Potter JD: Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol 2005, 23: 4713–4718. 10.1200/JCO.2005.00.133CrossRefPubMed
4.
go back to reference Bermejo JL, Hemminki K: Familial risk of cancer shortly after diagnosis of the first familial tumor. J Natl Cancer Inst 2005, 97: 1575–1579.CrossRefPubMed Bermejo JL, Hemminki K: Familial risk of cancer shortly after diagnosis of the first familial tumor. J Natl Cancer Inst 2005, 97: 1575–1579.CrossRefPubMed
5.
go back to reference Murff HJ, Spigel DR, Syngal S: Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. Jama 2004, 292: 1480–1489. 10.1001/jama.292.12.1480CrossRefPubMed Murff HJ, Spigel DR, Syngal S: Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. Jama 2004, 292: 1480–1489. 10.1001/jama.292.12.1480CrossRefPubMed
6.
go back to reference Chang E, Smedby KE, Hjalgrim H, Glimelius B, Adami HO: Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst 2006, 98: 61–68.CrossRefPubMed Chang E, Smedby KE, Hjalgrim H, Glimelius B, Adami HO: Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst 2006, 98: 61–68.CrossRefPubMed
7.
go back to reference Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004, 75: 1131–1135. 10.1086/426403PubMedCentralCrossRefPubMed Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004, 75: 1131–1135. 10.1086/426403PubMedCentralCrossRefPubMed
8.
go back to reference Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbanski K, Mitus J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Toloczko-Grabarek A, Medrek K, Masojc B, Mierzejewski M, Kowalska E, Narod SA, Lubinski J: Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 2005, 92: 19–24. 10.1007/s10549-005-1409-1CrossRefPubMed Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbanski K, Mitus J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Toloczko-Grabarek A, Medrek K, Masojc B, Mierzejewski M, Kowalska E, Narod SA, Lubinski J: Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 2005, 92: 19–24. 10.1007/s10549-005-1409-1CrossRefPubMed
9.
go back to reference Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson K: Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004, 1: e65. 10.1371/journal.pmed.0010065PubMedCentralCrossRefPubMed Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson K: Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004, 1: e65. 10.1371/journal.pmed.0010065PubMedCentralCrossRefPubMed
10.
go back to reference Kerber RA, O'Brien E: A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer 2005, 103: 1906–1915. 10.1002/cncr.20989CrossRefPubMed Kerber RA, O'Brien E: A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer 2005, 103: 1906–1915. 10.1002/cncr.20989CrossRefPubMed
11.
go back to reference Peto J, Easton DF, Matthews FE, Ford D, Swerdlow A: Cancer mortality in relatives of women with breast cancer: the OPCS Study. Int J Cancer 1996, 65: 275–283. 10.1002/(SICI)1097-0215(19960126)65:3<275::AID-IJC1>3.0.CO;2-XCrossRefPubMed Peto J, Easton DF, Matthews FE, Ford D, Swerdlow A: Cancer mortality in relatives of women with breast cancer: the OPCS Study. Int J Cancer 1996, 65: 275–283. 10.1002/(SICI)1097-0215(19960126)65:3<275::AID-IJC1>3.0.CO;2-XCrossRefPubMed
12.
go back to reference Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, Goldin LR: Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006, 108: 292–296. 10.1182/blood-2005-11-4620PubMedCentralCrossRefPubMed Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, Goldin LR: Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006, 108: 292–296. 10.1182/blood-2005-11-4620PubMedCentralCrossRefPubMed
13.
go back to reference Matikaine N, Pukkala E, Schleutker J, Tammela TL, Koivisto P, Sankila R, Kallioniemi OP: Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. Cancer Causes Control 2001, 12: 223–230. 10.1023/A:1011283123610CrossRefPubMed Matikaine N, Pukkala E, Schleutker J, Tammela TL, Koivisto P, Sankila R, Kallioniemi OP: Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. Cancer Causes Control 2001, 12: 223–230. 10.1023/A:1011283123610CrossRefPubMed
14.
go back to reference Hemminki K, Vaittinen P: Familial cancer in Sweden: population-based study. Int J Oncol 1997, 11: 273–280.PubMed Hemminki K, Vaittinen P: Familial cancer in Sweden: population-based study. Int J Oncol 1997, 11: 273–280.PubMed
15.
go back to reference Hemminki K, Li X, Plna K, Granstrom C, Vaittinen P: The nationwide Swedish family-cancer database-updated structure and familial rates. Acta Oncol 2001, 40: 772–777. 10.1080/02841860152619214CrossRefPubMed Hemminki K, Li X, Plna K, Granstrom C, Vaittinen P: The nationwide Swedish family-cancer database-updated structure and familial rates. Acta Oncol 2001, 40: 772–777. 10.1080/02841860152619214CrossRefPubMed
16.
go back to reference Hemminki K, Granstrom C, Chen B: The Swedish Family-Cancer Database: Update, Application to Colorectal Cancer and Cinical Relevance. Heredit Cancer in Clin Pract 2005, 3: 7–18.CrossRef Hemminki K, Granstrom C, Chen B: The Swedish Family-Cancer Database: Update, Application to Colorectal Cancer and Cinical Relevance. Heredit Cancer in Clin Pract 2005, 3: 7–18.CrossRef
17.
go back to reference IARC, (ed.): Cancer Incidence in Five Continents. IARC, Lyon; 2002. IARC, (ed.): Cancer Incidence in Five Continents. IARC, Lyon; 2002.
18.
go back to reference Hemminki K, Rawal R, Bermejo JL: Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 2005, 113: 312–315. 10.1002/ijc.20568CrossRefPubMed Hemminki K, Rawal R, Bermejo JL: Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 2005, 113: 312–315. 10.1002/ijc.20568CrossRefPubMed
19.
go back to reference Gronberg H: Prostate cancer epidemiology. Lancet 2003, 361: 859–864. 10.1016/S0140-6736(03)12713-4CrossRefPubMed Gronberg H: Prostate cancer epidemiology. Lancet 2003, 361: 859–864. 10.1016/S0140-6736(03)12713-4CrossRefPubMed
20.
go back to reference Pilebro B, Johansson R, Damber L, Damber JE, Stattin P: Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden. Scand J Urol Nephrol 2003, 37: 210–212. 10.1080/00365590310008064CrossRefPubMed Pilebro B, Johansson R, Damber L, Damber JE, Stattin P: Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden. Scand J Urol Nephrol 2003, 37: 210–212. 10.1080/00365590310008064CrossRefPubMed
21.
go back to reference Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren R, Varenhorst E, Johansson JE: Non-systematic screening for prostate cancer in Sweden-survey from the National Prostate Cancer Registry. Scand J Urol Nephrol 2003, 37: 461–465. 10.1080/00365590310015778CrossRefPubMed Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren R, Varenhorst E, Johansson JE: Non-systematic screening for prostate cancer in Sweden-survey from the National Prostate Cancer Registry. Scand J Urol Nephrol 2003, 37: 461–465. 10.1080/00365590310015778CrossRefPubMed
22.
go back to reference Hemminki K, Bermejo JL: Effects of screening for breast cancer on its age-incidence relationships and familial risk. Int J Cancer 2005, 117: 145–149. 10.1002/ijc.21149CrossRefPubMed Hemminki K, Bermejo JL: Effects of screening for breast cancer on its age-incidence relationships and familial risk. Int J Cancer 2005, 117: 145–149. 10.1002/ijc.21149CrossRefPubMed
23.
go back to reference Center for Epidemiology: Cancer Incidence in Sweden 2002. Stockholm: The National Board of Health and Welfare; 2004. Center for Epidemiology: Cancer Incidence in Sweden 2002. Stockholm: The National Board of Health and Welfare; 2004.
24.
go back to reference Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, de la Chapelle A: Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129: 415–421.CrossRefPubMed Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, de la Chapelle A: Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129: 415–421.CrossRefPubMed
25.
go back to reference Hemminki K, Eng C: Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet 2004, 41: 801–807. 10.1136/jmg.2004.022731PubMedCentralCrossRefPubMed Hemminki K, Eng C: Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet 2004, 41: 801–807. 10.1136/jmg.2004.022731PubMedCentralCrossRefPubMed
Metadata
Title
The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence
Authors
Kari Hemminki
Charlotta Granström
Jan Sundquist
Justo Lorenzo Bermejo
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 4/2006
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/1897-4287-4-4-186

Other articles of this Issue 4/2006

Hereditary Cancer in Clinical Practice 4/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine